

## Lymphoma

### REFERENCES

- Anderson GD, Rosito G et al. Drug interaction potential of soy extract and Panax ginseng. *J Clin Pharmacol* . 2003 Jun;43(6):643-8.
- Arditti FD, Rabinkov A et al. Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximab-alliinase conjugate. *Mol Cancer Ther* . 2005 Feb;4(2):325-31.
- Ashfaq MK, Zuberi HS et al. Vitamin E and beta-carotene affect natural killer cell function. *Int J Food Sci Nutr* . 2000;51 Suppl:S13-S20.
- Baris D, Zahm SH. Epidemiology of lymphomas. *Curr Opin Oncol* . 2000 Sep;12(5):383-94.
- Baxa DM, Yoshimura FK. Genistein reduces NF-kappa B in T lymphoma cells via a caspase-mediated cleavage of I kappa B alpha. *Biochem Pharmacol* . 2003 Sep 15;66(6):1009-18.
- Bertolini F, Fusetti L et al. Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma. *Leukemia* . 2000 Aug;14(8):1477-82.
- Betz O, Kranke P et al. [Is ginger a clinically relevant antiemetic? A systematic review of randomized controlled trials]. *Forsch Komplementarmed Klass Naturheilkd* . 2005 Feb;12(1):14-23.
- Brauninger A, Hansmann ML et al. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. *N Engl J Med* . 1999 Apr 22;340(16):1239-47.
- Bruno R, Ghisolfi L et al. Wine and tumors: study of resveratrol. *Drugs Exp Clin Res* . 2003;29(5-6):257-61.
- Buckley AR, Buckley DJ et al. Inhibition by genistein of prolactin-induced Nb2 lymphoma cell mitogenesis. *Mol Cell Endocrinol* . 1993 Dec;98(1):17-25.
- Buckley R, Shewring B et al. Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects. *Br J Nutr* . 2004 Sep;92(3):477-83.
- Calder PC, Yaqoob P et al. Fatty acids and lymphocyte functions. *Br J Nutr* . 2002 Jan;87 Suppl 1:S31-S48.
- Canellos GP. Lymphoma: present and future challenges. *Semin Hematol* . 2004 Oct;41(4 Suppl 7):26-31.
- Cartwright RA, Gurney KA et al. Sex ratios and the risks of haematological malignancies. *Br J Haematol* . 2002 Sep;118(4):1071-7.
- Catassi C, Fabiani E et al. Risk of non-Hodgkin lymphoma in celiac disease. *JAMA* . 2002 Mar 20;287(11):1413-9.
- Cerhan JR. New epidemiologic leads in the etiology of non-Hodgkin lymphoma in the elderly: the role of blood transfusion and diet. *Biomed Pharmacother* . 1997a;51(5):200-7.
- Cerhan JR, Anderson KE et al. Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. *Int J Cancer* . 2003 Sep 20;106(5):784-8.
- Cerhan JR, Vachon CM et al. Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia. *Cancer Epidemiol Biomarkers Prev* . 2002 Nov;11(11):1466-71.
- Cerhan JR, Wallace RB et al. Medical history risk factors for non-Hodgkin's lymphoma in older women. *J Natl Cancer Inst* . 1997b Feb 19;89(4):314-8.

Chanan-Khan A. Bcl-2 antisense therapy in hematologic malignancies. *Curr Opin Oncol* . 2004 Nov;16(6):581-5.

Chang ET, Smedby KE et al. Dietary factors and risk of non-hodgkin lymphoma in men and women. *Cancer Epidemiol Biomarkers Prev* . 2005 Feb;14(2):512-20.

Chatta GS, Dale DC. Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors. *Drugs Aging* . 1996 Jul;9(1):37-47.

Chen Q, Espey MG et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. *Proc Natl Acad Sci U S A* . 2005 Sep 20;102(38):13604-9.

Chiu BC, Cerhan JR et al. Diet and risk of non-Hodgkin lymphoma in older women. *JAMA* . 1996 May 1;275(17):1315-21.

Coffey J, Hodgson DC et al. Therapy of non-Hodgkin's lymphoma. *Eur J Nucl Med Mol Imaging* . 2003 Jun;30 Suppl 1:S28-S36.

Dalen H, Neuzil J. Alpha-tocopheryl succinate sensitises a T lymphoma cell line to TRAIL-induced apoptosis by suppressing NF-kappaB activation. *Br J Cancer* . 2003a Jan 13;88(1):153-8.

Dalen H, Neuzil J. Alpha-tocopheryl succinate sensitises a T lymphoma cell line to TRAIL-induced apoptosis by suppressing NF-kappaB activation. *Br J Cancer* . 2003b Jan 13;88(1):153-8.

Danese C, Angrisani L et al. [A five year follow-up of a Primary Effusion Lymphoma HHV-8 related in an HIV-negative elderly patient]. *Clin Ter* . 2004 Nov;155(11-12):543-6.

Dasgupta J, Sanyal U et al. Vitamin E--its status and role in leukemia and lymphoma. *Neoplasma* . 1993;40(4):235-40.

De SE, Fierro L et al. Tobacco, alcohol, diet and risk of non-Hodgkin's lymphoma: a case-control study in Uruguay. *Leuk Res* . 1998 May;22(5):445-52.

DeNardo GL. Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspective. *Semin Oncol* . 2005 Feb;32(1 Suppl 1):S27-S35.

Dillman RO. Radioimmunotherapy of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. *Curr Hematol Rep* . 2003 Jan;2(1):30-7.

Dulak J. Nutraceuticals as anti-angiogenic agents: hopes and reality. *J Physiol Pharmacol* . 2005 Mar;56 Suppl 1:51-69.

Escalon MP, Liu NS et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. *Cancer* . 2005 May 15;103(10):2091-8.

Feugier P, Van HA et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol* . 2005 May 2.

Fiorilli M, Mecucci C et al. HCV-associated lymphomas. *Rev Clin Exp Hematol* . 2003 Dec;7(4):406-23.

Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. *Oncogene* . 2004 Aug 23;23(38):6524-34.

Floret N, Mauny F et al. Dioxin emissions from a solid waste incinerator and risk of non-Hodgkin lymphoma. *Epidemiology* . 2003 Jul;14(4):392-8.

Forero A, Lobuglio AF. History of antibody therapy for non-Hodgkin's lymphoma. *Semin Oncol* . 2003 Dec;30(6 Suppl 17):1-5.

Franco M, Rugge M et al. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori: scratch and win. *Scand J Gastroenterol* . 2005 Jan;40(1):115-9.

Freedman DM, Cantor KP et al. A case-control study of nitrate in drinking water and non-Hodgkin's lymphoma in Minnesota. *Arch Environ Health* . 2000 Sep;55(5):326-9.

Gaisbauer M, Langosch A. [Raw food and immunity]. *Fortschr Med* . 1990 Jun 10;108(17):338-40.

Gescher A. Polyphenolic phytochemicals versus non-steroidal anti-inflammatory drugs: which are better cancer chemopreventive agents? *J Chemother* . 2004 Nov;16 Suppl 4:3-6.

Giannoulis E, Economopoulos T et al. The prevalence of hepatitis C and hepatitis G virus infection in patients with B cell non-Hodgkin lymphomas in Greece: a Hellenic Cooperative Oncology Group Study. *Acta Haematol* . 2004;112(4):189-93.

Glaser SL. Black-white differences in Hodgkin's disease incidence in the United States by age, sex, histology subtype and time. *Int J Epidemiol* . 1991 Mar;20(1):68-75.

Grillo-Lopez AJ. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma. *Semin Oncol* . 2005 Feb;32(1 Suppl 1):S44-S49.

Groves FD, Linet MS et al. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. *J Natl Cancer Inst* . 2000 Aug 2;92(15):1240-51.

Hagenbeek A. Future trends in radioimmunotherapy. *Semin Oncol* . 2005 Feb;32(1 Suppl 1):S57-S62.

Han SS, Chung ST et al. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. *Clin Immunol* . 1999 Nov;93(2):152-61.

Hansmann ML, Kuppers R. Pathology and "molecular histology" of Hodgkin's disease and the border to non-Hodgkin's lymphomas. *Baillieres Clin Haematol* . 1996 Sep;9(3):459-77.

Harris NL. Hodgkin's disease: classification and differential diagnosis. *Mod Pathol* . 1999 Feb;12(2):159-75.

Hauke RJ, Armitage JO. A new approach to non-Hodgkin's lymphoma. *Intern Med* . 2000 Mar;39(3):197-208.

Heimli H, Finstad HS et al. Necrosis and apoptosis in lymphoma cell lines exposed to eicosapentaenoic acid and antioxidants. *Lipids* . 2001 Jun;36(6):613-21.

Heimli H, Giske C et al. Eicosapentaenoic acid promotes apoptosis in Ramos cells via activation of caspase-3 and -9. *Lipids* . 2002 Aug;37(8):797-802.

Heimli H, Hollung K et al. Eicosapentaenoic acid-induced apoptosis depends on acyl CoA-synthetase. *Lipids* . 2003 Mar;38(3):263-8.

Holmes FF, Wilson J et al. Biology of cancer and aging. *Cancer* . 1991 Dec 1;68(11 Suppl):2525-6.

Iarussi D, Auricchio U et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. *Mol Aspects Med* . 1994;15 Suppl:s207-s212.

Irwin D, Kaplan L. Clinical aspects of HIV-related lymphoma. *Curr Opin Oncol* . 1993 Sep;5(5):852-60.

Jackson RM, Rice DH. Acute bacterial sinusitis and diabetes mellitus. *Otolaryngol Head Neck Surg* . 1987 Nov;97(5):469-73.

Jarrett RF. Risk factors for Hodgkin's lymphoma by EBV status and significance of detection of EBV genomes in serum of patients with EBV-associated Hodgkin's lymphoma. *Leuk Lymphoma* . 2003;44 Suppl 3:S27-S32.

Jazirehi AR, Bonavida B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. *Mol Cancer Ther* . 2004 Jan;3(1):71-84.

Jetsrisuparb A, Wiangnon S et al. Rituximab combined with CHOP for successful treatment of aggressive recurrent, pediatric B-cell large cell non-Hodgkin's Lymphoma. *J Pediatr Hematol Oncol* . 2005 Apr;27(4):223-6.

Jimenez-Zepeda VH, Jimenez-Zepeda RJ. [Non-Hodgkin's lymphoma: biologic classification, diagnosis and treatment]. *Gac Med Mex* . 1998 Jul;134(4):443-63.

Jones DE. Fat is an immuno-regulatory issue. *Hepatology* . 2005 Oct;42(4):755-8.

Jose BO, Koerner P et al. Hodgkin's lymphoma in adults--clinical features. *J Ky Med Assoc* . 2005 Jan;103(1):15-7.

Kakizoe T. Chemoprevention of cancer--focusing on clinical trials. *Jpn J Clin Oncol* . 2003 Sep;33(9):421-42.

Kaplan LD. AIDS-associated lymphoma. *Baillieres Clin Haematol* . 1990 Jan;3(1):139-51.

Kato I, Koenig KL et al. History of antibiotic use and risk of non-Hodgkin's lymphoma (NHL). *Int J Cancer* . 2003 Oct 20;107(1):99-105.

Kato I, Koenig KL et al. Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin's lymphoma (NHL) (United States). *Cancer Causes Control* . 2002 Dec;13(10):965-74.

Katsuno Y, Koyama Y et al. Apoptosis-inducing activity of a driselase digest fraction of green tea residue. *Biosci Biotechnol Biochem* . 2001 Jan;65(1):198-201.

Kempf W, Kettelhack N et al. Topical and systemic retinoid therapy for cutaneous T-cell lymphoma. *Hematol Oncol Clin North Am* . 2003 Dec;17(6):1405-19.

Kohn LD, Wallace B et al. Is type 2 diabetes an autoimmune-inflammatory disorder of the innate immune system? *Endocrinology* . 2005 Oct;146(10):4189-91.

Krueger GR, Guenther A et al. Human herpesvirus-6 (HHV-6) in Hodgkin's disease: cellular expression of viral antigens as compared to oncogenes met and fes, tumor suppressor gene product p53, and interleukins 2 and 6. *In Vivo* . 1994 Jul;8(4):501-16.

Kuppers R, Schwering I et al. Biology of Hodgkin's lymphoma. *Ann Oncol* . 2002;13 Suppl 1:11-8.

Lagman R, Walsh D. Dangerous nutrition? Calcium, vitamin D, and shark cartilage nutritional supplements and cancer-related hypercalcemia. *Support Care Cancer* . 2003 Apr;11(4):232-5.

Laurie SA, Miller VA et al. Phase I study of green tea extract in patients with advanced lung cancer. *Cancer Chemother Pharmacol* . 2005 Jan;55(1):33-8.

Lavoie JC, Connors JM et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. *Blood* . 2005 May 3.

Lee WJ, Cantor KP et al. Non-Hodgkin's lymphoma among asthmatics exposed to pesticides. *Int J Cancer* . 2004 Aug 20;111(2):298-302.

Lenz G, Dreyling M et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). *J Clin Oncol* . 2005 Mar 20;23(9):1984-92.

Lewington V. Development of 131I-tositumomab. *Semin Oncol* . 2005 Feb;32(1 Suppl 1):S50-S56.

Lim ST, Levine AM. Non-AIDS-defining cancers and HIV infection. *Curr Infect Dis Rep* . 2005 May;7(3):227-34.

Lister TA, Crowther D et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. *J Clin Oncol* . 1989 Nov;7(11):1630-6.

Litam P, Swan F et al. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. *Ann Intern Med* . 1991 May 15;114(10):855-60.

Lyman GH. A predictive model for neutropenia associated with cancer chemotherapy. *Pharmacotherapy* . 2000 Jul;20(7 Pt 2):104S-11S.

Macklis RM. Radioimmunotherapy as a Therapeutic Option for Non-Hodgkin's Lymphoma. *Semin Radiat Oncol*. 2007 Jul;17(3):176-83.

Mahrle G, Thiele B. Retinoids in cutaneous T cell lymphomas. *Dermatologica* . 1987;175 Suppl 1:145-50.

Maloney DG. Contraception and immunotherapy: anti-CD20 mechanisms of action and targets. *Semin Oncol* . 2005 Feb;32(1 Suppl 1):S19-S26.

Martin S, Fischer C et al. LightCycler-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy. *Eur J Haematol* . 2005 Apr;74(4):282-92.

Mathiasen IS, Colston KW et al. EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells. *J Steroid Biochem Mol Biol* . 1993 Sep;46(3):365-71.

Mellibovsky L, Diez A et al. Long-standing remission after 25-OH D3 treatment in a case of chronic myelomonocytic leukaemia. *Br J Haematol* . 1993 Dec;85(4):811-2.

Meyskens FL, Jr., Kopecky KJ et al. Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. *Leuk Res* . 1995 Sep;19(9):605-12.

Miyoshi N, Nakamura Y et al. Dietary ginger constituents, galanals A and B, are potent apoptosis inducers in Human T lymphoma Jurkat cells. *Cancer Lett* . 2003 Sep 25;199(2):113-9.

Mohammad RM, Al-Katib A et al. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. *Mol Cancer Ther* . 2003 Dec;2(12):1361-8.

Morgensztern D, Rosado M et al. Prevalence of hepatitis C infection in patients with non-Hodgkin's lymphoma in South Florida and review of the literature. *Leuk Lymphoma* . 2004 Dec;45(12):2459-64.

Mukai HY, Okoshi Y et al. Successful treatment of a patient with subcutaneous panniculitis-like T-cell lymphoma with high-dose chemotherapy and total body irradiation. *Eur J Haematol* . 2003 Jun;70(6):413-6.

Muller AM, Ihorst G et al. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. *Ann Hematol* . 2005 Jan;84(1):1-12.

Nagy B, Mucsi I et al. Chemosensitizing effect of vitamin C in combination with 5-fluorouracil in vitro. *In Vivo* . 2003 May;17(3):289-92.

Nakai S, Masaki T et al. Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): A case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma. *Oncol Rep* . 2005 Jun;13(6):1065-8.

Natazuka T, Manabe Y et al. Association between non-insulin dependent diabetes mellitus and non-Hodgkin's lymphoma. *BMJ* . 1994 Nov 12;309(6964):1269.

Nicot C. Current views in HTLV-I-associated adult T-cell leukemia/lymphoma. *Am J Hematol* . 2005 Mar;78(3):232-9.

Noronha V, Shafi NQ et al. Primary non-Hodgkin's lymphoma of the liver. *Crit Rev Oncol Hematol* . 2005 Mar;53(3):199-207.

Ogilvie GK, Fettman MJ et al. Effect of fish oil, arginine, and doxorubicin chemotherapy on remission and survival time for dogs with lymphoma: a double-blind, randomized placebo-controlled study. *Cancer* . 2000 Apr 15;88(8):1916-28.

Park JW, Choi YJ et al. Chemopreventive agent resveratrol, a natural product derived from grapes, reversibly inhibits progression through S and G2 phases of the cell cycle in U937 cells. *Cancer Lett* . 2001 Feb 10;163(1):43-9.

Pasqualucci L, Bereschenko O et al. Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. *Leuk Lymphoma* . 2003;44 Suppl 3:S5-12.

Pedersen LM, Klausen TW et al. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. *Ann Hematol* . 2005 Apr 15.

Pisters KM, Newman RA et al. Phase I trial of oral green tea extract in adult patients with solid tumors. *J Clin Oncol* . 2001 Mar 15;19(6):1830-8.

Plat J, Mensink RP. Food components and immune function. *Curr Opin Lipidol* . 2005 Feb;16(1):31-7.

- Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. *Drugs* . 2003;63(8):803-43.
- Prasad SB, Giri A et al. Use of subtherapeutic dose of cisplatin and vitamin C against murine Dalton's lymphoma. *Pol J Pharmacol Pharm* . 1992 Jul;44(4):383-91.
- Quintana PJ, Delfino RJ et al. Adipose tissue levels of organochlorine pesticides and polychlorinated biphenyls and risk of non-Hodgkin's lymphoma. *Environ Health Perspect* . 2004 Jun;112(8):854-61.
- Ranjan D, Johnston TD et al. Enhanced apoptosis mediates inhibition of EBV-transformed lymphoblastoid cell line proliferation by curcumin. *J Surg Res* . 1999 Nov;87(1):1-5.
- Rigacci L, Carrai V et al. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with ciprofloxacin for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study. *Cancer* . 2005 Mar 1;103(5):970-7.
- Riley MB, Gordon LI. Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). *Semin Oncol Nurs*. 2004 Feb;20(1 Suppl 1):8-13.
- Rossing N. [Raw food against cancer. A report from a study done by the Society for Alternative Medicine]. *Ugeskr Laeger* . 1988 Mar 7;150(10):613-5.
- Russell RM. The vitamin A spectrum: from deficiency to toxicity. *Am J Clin Nutr* . 2000 Apr;71(4):878-84.
- Scharfenberg K, Wagner R et al. The cytotoxic effect of ajoene, a natural product from garlic, investigated with different cell lines. *Cancer Lett* . 1990 Sep;53(2-3):103-8.
- Schneider RJ, Seibert K et al. Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. *Cancer* . 1980 Jul 1;46(1):139-43.
- Seve P, Renaudier P et al. Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma: a cross-sectional study in Lyon, France. *Eur J Gastroenterol Hepatol* . 2004 Nov;16(12):1361-5.
- Smedby KE, Akerman M et al. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. *Gut* . 2005 Jan;54(1):54-9.
- Sonet A, Theate I et al. Clinical and pathological features of 14 non-Hodgkin's lymphomas associated with coeliac disease. *Acta Clin Belg* . 2004 May;59(3):143-51.
- Tajima M. [Chronic cardiotoxicity of anthracycline derivatives and possible prevention by coenzyme Q10]. *Gan No Rinsho* . 1984 Jul;30(9 Suppl):1211-6.
- Thompson LD, Fisher SI et al. HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases. *Am J Clin Pathol* . 2004 May;121(5):727-38.
- Tsubaki K, Horiuchi A et al. [Investigation of the preventive effect of CoQ10 against the side-effects of anthracycline antineoplastic agents]. *Gan To Kagaku Ryoho* . 1984 Jul;11(7):1420-7.
- Tulpule A, Levine A. AIDS-related lymphoma. *Blood Rev* . 1999 Sep;13(3):147-50.
- Vallisa D, Bernuzzi P et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. *J Clin Oncol* . 2005 Jan 20;23(3):468-73.
- Vamvakas EC. Allogeneic blood transfusion as a risk factor for the subsequent development of non-Hodgkin's lymphoma. *Transfus Med Rev* . 2000 Jul;14(3):258-68.
- van Loghem JJ. [Raw food to cure cancer.]. *Ned Tijdschr Geneesk* . 1951 Feb 10;95(6):482-3.
- Waddell BL, Zahm SH et al. Agricultural use of organophosphate pesticides and the risk of non-Hodgkin's lymphoma among male

farmers (United States). *Cancer Causes Control* . 2001 Aug;12(6):509-17.

Walle T, Hsieh F et al. High absorption but very low bioavailability of oral resveratrol in humans. *Drug Metab Dispos* . 2004 Dec;32(12):1377-82.

Wang SQ. [Electrocardiogram analysis of adriamycin cardiotoxicity in 160 cases]. *Zhonghua Zhong Liu Za Zhi* . 1991 Jan;13(1):71-3.

Ward MH, Mark SD et al. Drinking water nitrate and the risk of non-Hodgkin's lymphoma. *Epidemiology* . 1996 Sep;7(5):465-71.

Weisenburger DD. Environmental epidemiology of non-Hodgkin's lymphoma in eastern Nebraska. *Am J Ind Med* . 1990;18(3):303-5.

Wieder R, Novick SC et al. Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. *Invest New Drugs* . 2003 Nov;21(4):445-52.

Wiseman GA, Witzig TE. Yttrium-90 (90Y ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's Lymphoma. *Cancer Biother Radiopharm* . 2005 Apr;20(2):185-8.

Witzig TE, Gordon LI, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. *J Clin Oncol*. 2002 May 15;20(10):2453-63.

Witzig TE, Molina A, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. *Cancer*. 2007 May 1;109(9):1804-10.

Wotherspoon AC. Gastric lymphoma of mucosa-associated lymphoid tissue and *Helicobacter pylori*. *Annu Rev Med* . 1998;49:289-99.

Wu Y, Chen Y et al. Anticancer activities of curcumin on human Burkitt's lymphoma. *Zhonghua Zhong Liu Za Zhi* . 2002a Jul;24(4):348-52.

Wu Y, Chen Y et al. Anticancer activities of curcumin on human Burkitt's lymphoma. *Zhonghua Zhong Liu Za Zhi* . 2002c Jul;24(4):348-52.

Wu Y, Chen Y et al. Anticancer activities of curcumin on human Burkitt's lymphoma. *Zhonghua Zhong Liu Za Zhi* . 2002b Jul;24(4):348-52.

Wu Y, Chen Y et al. Anticancer activities of curcumin on human Burkitt's lymphoma. *Zhonghua Zhong Liu Za Zhi* . 2002d Jul;24(4):348-52.

Younes A. New treatment strategies for aggressive lymphoma. *Semin Oncol* . 2004 Dec;31(6 Suppl 15):10-3.

Zhang C, Duvic M. Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. *Dermatol Ther* . 2003;16(4):322-30.

Zhang S, Hunter DJ et al. Dietary fat and protein in relation to risk of non-Hodgkin's lymphoma among women. *J Natl Cancer Inst* . 1999 Oct 20;91(20):1751-8.

Zhang SM, Hunter DJ et al. Intakes of fruits, vegetables, and related nutrients and the risk of non-Hodgkin's lymphoma among women. *Cancer Epidemiol Biomarkers Prev* . 2000 May;9(5):477-85.

Zheng T, Holford TR et al. Diet and nutrient intakes and risk of non-Hodgkin's lymphoma in Connecticut women. *Am J Epidemiol* . 2004 Mar 1;159(5):454-66.

your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.